India, Aug. 14 -- Inhibrx Biosciences Inc. (INBX) has a key catalyst to watch in October involving one of its clinical drug candidates, Ozekibart.
Ozekibart, formerly known as INBRX-109, is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation.
The company is exploring Ozekibart in the following trials:
-- A registration-enabling phase II trial in patients with unresectable or metastatic conventional chondrosarcoma, dubbed ChonDRAgon.
-- A phase I trial in patients with Ewing sarcoma and colorectal adenocarcinoma.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The phase II trial in unresectable or metas...